David Tougeron

11.0k total citations · 2 hit papers
223 papers, 3.9k citations indexed

About

David Tougeron is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, David Tougeron has authored 223 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Oncology, 96 papers in Pulmonary and Respiratory Medicine and 70 papers in Surgery. Recurrent topics in David Tougeron's work include Colorectal Cancer Treatments and Studies (92 papers), Gastric Cancer Management and Outcomes (60 papers) and Genetic factors in colorectal cancer (60 papers). David Tougeron is often cited by papers focused on Colorectal Cancer Treatments and Studies (92 papers), Gastric Cancer Management and Outcomes (60 papers) and Genetic factors in colorectal cancer (60 papers). David Tougeron collaborates with scholars based in France, United States and Italy. David Tougeron's co-authors include Julien Taı̈eb, Gaëlle Tachon, Frank A. Sinicrope, Romain Cohen, Camille Evrard, Pierre Michel, Lucie Karayan‐Tapon, Thierry Lecomte, Violaine Randrian and Jean–Marc Phelip and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

David Tougeron

201 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

2022 220 citations Thierry André, David Tougeron et al. Journal of Clinical Oncology profile →
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment

2022 147 citations Julien Taı̈eb, Romain Cohen et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Tougeron France	36	2.4k	1.4k	1.4k	1.0k	690	223	3.9k
Aziz Zaanan France	33	2.2k 0.9×	1.2k 0.9×	1.0k 0.7×	1.4k 1.3×	748 1.1×	136	3.6k
Tomohiro Nishina Japan	35	2.7k 1.1×	2.2k 1.6×	1.1k 0.8×	645 0.6×	450 0.7×	231	4.3k
Ilhan Celik Germany	15	2.8k 1.2×	1.6k 1.2×	682 0.5×	911 0.9×	605 0.9×	31	3.9k
Hendrik Bläker Germany	37	1.8k 0.7×	634 0.5×	840 0.6×	1.2k 1.2×	870 1.3×	136	3.6k
Satoru Iwasa Japan	30	2.7k 1.1×	1.9k 1.3×	1.3k 0.9×	357 0.3×	315 0.5×	255	4.4k
Hisato Kawakami Japan	32	2.7k 1.1×	1.6k 1.1×	631 0.5×	666 0.6×	508 0.7×	179	3.8k
Ravit Geva Israel	33	4.1k 1.7×	1.6k 1.2×	880 0.6×	662 0.6×	827 1.2×	134	5.3k
Seong Hyeon Yun South Korea	37	3.5k 1.5×	1.0k 0.7×	2.2k 1.6×	614 0.6×	362 0.5×	207	4.5k
Yoshito Komatsu Japan	37	4.1k 1.7×	3.5k 2.5×	2.2k 1.6×	900 0.9×	737 1.1×	319	6.6k
Salah‐Eddin Al‐Batran Germany	39	3.2k 1.3×	3.3k 2.4×	1.9k 1.4×	637 0.6×	532 0.8×	214	5.6k

Countries citing papers authored by David Tougeron

Since Specialization

Citations

This map shows the geographic impact of David Tougeron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Tougeron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Tougeron more than expected).

Fields of papers citing papers by David Tougeron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Tougeron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Tougeron. The network helps show where David Tougeron may publish in the future.

Co-authorship network of co-authors of David Tougeron

This figure shows the co-authorship network connecting the top 25 collaborators of David Tougeron. A scholar is included among the top collaborators of David Tougeron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Tougeron. David Tougeron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Randrian, Violaine, Fabienne Portales, Olivier Bouché, et al.. (2025). The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors. Journal of Neuro-Oncology. 172(1). 229–238.

Lefèvre, Jérémie H., Olivier Dubreuil, Raphaël Colle, et al.. (2025). Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES). Digestive and Liver Disease. 58(1). 51–55.

Taı̈eb, Julien, Margherita Ambrosini, Sara Lonardi, et al.. (2025). Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 13(1). e010424–e010424. 2 indexed citations

Xu, Jianming, Ken Kato, Yongqian Shu, et al.. (2024). 395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306. Annals of Oncology. 35. S159–S159. 1 indexed citations

Bachet, Jean‐Baptiste, Déwi Vernerey, Christophe Boisson, et al.. (2024). 532P G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study. Annals of Oncology. 35. S447–S447. 1 indexed citations

Roth, Gaël S., Anna Pellat, Guillaume Piessen, et al.. (2024). A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort. ESMO Open. 9(12). 103988–103988.

Lemanski, C., P. Pommier, Karine Le Malicot, et al.. (2024). Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE. British Journal of Cancer. 130(5). 769–776. 1 indexed citations

Bekaii‐Saab, Tanios, Arvind Dasari, Cathy Eng, et al.. (2024). Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2.. Journal of Clinical Oncology. 42(16_suppl). 3579–3579.

Ambrosini, Margherita, David Tougeron, Dominik Paul Modest, et al.. (2024). BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. European Journal of Cancer. 210. 114290–114290. 7 indexed citations

10.

Gallois, Claire, Édouard Auclin, Elisabeth Bergen, et al.. (2023). 625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study. Annals of Oncology. 34. S446–S446. 4 indexed citations

11.

Hémont, Caroline, Nicolas Chapelle, David Tougeron, et al.. (2023). Atrophic Gastritis and Autoimmunity: Results from a Prospective, Multicenter Study. Diagnostics. 13(9). 1599–1599. 9 indexed citations

12.

Saberzadeh-Ardestani, Bahar, Jeremy Jones, Robert R. McWilliams, et al.. (2023). Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting. European Journal of Cancer. 196. 113433–113433. 7 indexed citations

13.

André, Thierry, David Tougeron, Guillaume Piessen, et al.. (2022). Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of Clinical Oncology. 41(2). 255–265. 220 indexed citations breakdown →

14.

Pernot, Simon, Olivier Pellerin, Laurent Mineur, et al.. (2022). Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Digestive and Liver Disease. 54(3). 324–330. 6 indexed citations

15.

Lepage, Côme, Astrid Lièvre, Laëtitia Dahan, et al.. (2022). Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study. European Journal of Cancer. 175. 31–40. 13 indexed citations

16.

Hautefeuille, Vincent, Édouard Auclin, Astrid Lièvre, et al.. (2022). Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. British Journal of Cancer. 126(10). 1394–1400. 5 indexed citations

17.

Pernot, Simon, Olivier Pellerin, Pascal Artru, et al.. (2020). Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. British Journal of Cancer. 123(4). 518–524. 19 indexed citations

18.

Phelip, Jean–Marc, David Tougeron, David Léonard, et al.. (2019). Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Digestive and Liver Disease. 51(10). 1357–1363. 70 indexed citations

19.

Pernot, Simon, Olivier Dubreuil, Thomas Aparicio, et al.. (2018). Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. British Journal of Cancer. 119(4). 424–428. 24 indexed citations

20.

Brieau, Bertrand, Céline Lepère, Thomas Walter, et al.. (2015). Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma. Medicine. 94(42). e1864–e1864. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact